TY - JOUR T1 - Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3391 VL - 58 IS - suppl 65 SP - PA3391 AU - Jorge Maspero AU - Huib A. M. Kerstjens AU - Kenneth R. Chapman AU - Richard Van Zyl-Smit AU - Ana-Maria Tanase AU - David Lawrence AU - Abhijit Pethe AU - Karen Mezzi AU - Peter D'Andrea Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3391.abstract N2 - Introduction: GINA 2020 recommends high-dose ICS/LABA as preferred controller for patients (pts) with asthma in step 5 therapy. This post hoc analysis from IRIDIUM study evaluated efficacy of once-daily high-dose (160/150/50 µg) vs medium-dose (80/150/50 µg) MF/IND/GLY in pts with inadequately controlled asthma (ACQ-7≥1.5) with high-dose ICS/LABA prior to enrolment.Methods: IRIDIUM (NCT02571777) was a 52-wk, randomised, double-blind, parallel-group study in pts with symptomatic asthma (ACQ-7≥1.5), ≥1 exacerbation in previous year and predicted FEV1 <80%. Trough FEV1 at Wk 26 and annualised rate of exacerbations over 52 wks were assessed.Results: In pts with inadequately controlled asthma with high-dose ICS/LABA (37% at baseline), high-dose MF/IND/GLY showed comparable improvements in trough FEV1 at Wk 26 and relevant reduction in exacerbation rate (non-significant in this underpowered analysis) vs medium-dose MF/IND/GLY (Table).Conclusion: In pts with inadequately controlled asthma with high-dose ICS/LABA, comparable FEV1 improvement and a trend toward exacerbation rate reduction were seen with high-dose than medium-dose MF/IND/GLY. These results suggest high-dose MF/IND/GLY as step-up therapy provides better clinical benefit than medium-dose MF/IND/GLY. FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3391.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -